Health Care Supplies

Bioeasy

Bioeasy released FY2025 Annual Earnings on April 26 After-Market (BJT), actual revenue CNY 263.23 M, actual EPS CNY 0.03

Bioeasy released FY2025 Q4 earnings on April 26 After-Market BJT, actual revenue CNY 77.6 M, actual EPS CNY -0.0068

Bioeasy released FY2026 Q1 earnings on April 26 After-Market (BJT), actual revenue CNY 57.64 M, actual EPS CNY -0.0253

Bioeasy to Release FY2026 Q1 Earnings on April 27 After-Market (BJT)

Bioeasy FY2025 Annual Earnings Release on April 27, 2026 After-Market (BJT)

Bioeasy released FY2025 9 Months Earnings on October 27 After-Market (BJT), Actual Revenue: CNY 185.63 M, Actual EPS: CNY 0.0452

Bioeasy released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 76.35 M, actual EPS CNY 0.0394

Bioeasy FY2025 Q3 Earnings Release on October 28, 2025 After-Market (BJT)

Bioeasy released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue CNY 109.29 M, actual EPS CNY 0.0058

Bioeasy released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 59.94 M, actual EPS CNY 0.014

Bioeasy to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

EasyBio's Controlling Shareholder and Actual Controller Plan to Reduce Shareholding

Yirui Bio Sees Significant Growth in Pet Diagnostic Sales

Eraibio's Controlling Shareholder's Selling Plan Completed

Yirui Bio signs partnership and distribution agreement with Chr. Hansen A/S

Bioeasy released FY2024 Q4 earnings on April 24 After-Market BJT, actual revenue CNY 66.2 M, actual EPS CNY 0.0261

Bioeasy released FY2025 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 49.34 M, actual EPS CNY -0.0083

Bioeasy released FY2024 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 224.25 M, actual EPS CNY 0.04

Bioeasy to Release FY2025 Q1 Earnings on April 25 After-Market BJT

Bioeasy FY2024 Annual Earnings Release Scheduled for April 25, 2025 After-Market BJT

300942

Bioeasy released its third-quarter report for 2025, with operating revenue of 186 million yuan in the first three quarters, a year-on-year increase of 17.45%. The net profit attributable to the parent company was 18.023 million yuan, an increase of 362.49%; the net profit excluding non-recurring gains and losses was 3.7285 million yuan, an increase of 137.78%. The basic earnings per share were 0.0449 yuan

Zhitong

Bioeasy released its performance for the first three quarters, with a net profit attributable to the parent company of 18.023 million yuan, an increase of 362.49%

Bioeasy's controlling shareholder, Bioeasy Venture Capital, and its concerted parties plan to reduce their holdings by no more than 3% through centralized bidding or block trading within the three months from November 3, 2025, to February 2, 2026

Bioeasy's controlling shareholder and its concerted parties plan to reduce their holdings by no more than 3%

Bioeasy announced that its operating revenue in the first half of 2025 was 109 million yuan, a year-on-year increase of 5.44%. The net profit attributable to shareholders of the listed company was 2.3395 million yuan, compared to a loss of 1.5595 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

Bioeasy: Net profit of 2.3395 million yuan in the first half of 2025, turning a profit from a loss year-on-year

Bioeasy announced that its controlling shareholder, Bioeasy Venture Capital Co., Ltd., plans to reduce its holdings by no more than 3.5312 million shares, accounting for 0.88% of the company's total share capital; the actual controller, Zhu Hai, plans to reduce his holdings by no more than 7.5214 million shares, accounting for 1.87% of the company's total share capital. The reduction will be conducted through centralized bidding or block trading, with the reduction period from July 28, 2025, to October 27, 2025. The reason for the reduction is due to personal funding needs

Bioeasy: Yi Rui Venture Capital and Zhu Hai plan to reduce their holdings of the company's shares by 0.88% and 1.87%, respectively

600530

002551

300633

300981

300676

The healthcare sector surged, with GMF hitting the limit up, followed by JIAODA ONLLY, SONOSCAPE, ZHYL, BGI Genomics, and Bioeasy among the top gainers

JIAODA ONLLY

SONOSCAPE

ZHYL

BGI Genomics

The healthcare sector rises, GMF hits the limit up

On March 19th, Shenzhen Bioeasy Technology Co., Ltd., Shenzhen Shenlan Technology Co., Ltd., and Yunnan Provincial Grain and Oil Science Research Institute signed a strategic cooperation agreement. This cooperation marks the official launch of in-depth collaboration among the three parties in the fields of grain and oil quality testing technology research and development, standard formulation, and industrial application. The three parties will establish a joint laboratory to promote the in-depth application of rapid testing technology in grain storage and processing

Bioeasy, Shenlan Technology, and Yunnan Academy of Grain and Oil Sciences have reached a strategic cooperation

Bioeasy announced that the controlling shareholder and several shareholders plan to reduce their holdings by no more than 13.0129 million shares through centralized bidding or block trading from April 11, 2025, to July 10, 2025

Bioeasy multiple shareholders plan to reduce their holdings by no more than 13.0129 million shares

Bioeasy announced that its controlling shareholder and actual controller's concerted actors, Yidaru and Yikaire, as well as Wang Tianyi, who holds more than 5% of the shares, plan to reduce their holdings in the company from April 11, 2025, to July 10, 2025. Yidaru intends to reduce its holdings by no more than 411,200 shares, Yikaire intends to reduce its holdings by no more than 575,700 shares, and Wang Tianyi intends to reduce his holdings by no more than 12,026,000 shares, with the reason for the reduction being funding needs

Bioeasy: Yidari, Yikaire, and Wang Tianyi plan to reduce their holdings of the company's shares by no more than 3.25% each

According to the Qichacha APP, recently, Bioeasy ZhiJia Biotechnology Co., Ltd. was established, with Liu Fengrong as the legal representative and a registered capital of 5 million yuan. The business scope includes: research and development of bio-based material technology; optimization of fermentation process technology; promotion services for new material technology; research and application of cell technology, etc. Qichacha's equity penetration shows that the company is jointly held by Bioeasy and others

HIFICHEM

Valiant

NEWLIFE

HLSH

Shaanxi Lighte

Evergreen New Material Technology

DING LONG

BAMC

Niutech

Jilin OLED

Bioeasy and others establish a new company including cell technology research and development business

300760

688075

Weilide Biomedical focuses on the in vitro diagnostic market and plans to auction 2,808 shares from February 4 to 6, with a starting price of 50 yuan, and is expected to be listed on February 24. The revenue for 2023 is 941 million yuan, with a net profit after tax of 152 million yuan. The revenue for 2024 is expected to be 991 million yuan, a year-on-year increase of 5.36%. The company emphasizes that in vitro testing and preventive medicine are important trends in global health management, and it will deepen the application of digital medical technology to promote stable growth in operations

money.udn.com

Mindray

Assure Tech

Huakang Clean

HAIER BIOMEDICAL

WHOLE SHINE MEDICAL

Skyray Instrument

YIDU TECH

Realcan

Weilider Biomedical focuses on in vitro diagnostics and will start bidding on the 4th, with an expected listing on the 24th

Bioeasy(300942.SZ)